Skip to main content

LCD L34454: Colonoscopy/Sigmoidoscopy/Proctosigmoidoscopy

LCD L34454, Colonoscopy/Sigmoidoscopy/Proctosigmoidoscopy, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2024-12-19 and first in force 2015-10-01. The policy text runs 834 words, and its billing and coding article A55069 lists 3 ICD-10-CM codes that support medical necessity for 7 procedure codes. 1 other contractor version share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 564 covered ICD-10-CM codes: 142 more codes than L34005 (CGS Administrators, LLC, 422 codes, revised 2026-01-22).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2024-12-19
Original effective
2015-10-01
Policy text
834 words
Covered ICD-10 codes (articles)
564

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L34454
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding articles A55069, A55227, A56632: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A55069 (Billing and Coding: Screening Colonoscopy Converted to a Diagnostic and/or Therapeutic Colonoscopy), Billing and Coding A55227 (Billing and Coding: Incomplete Colonoscopy/Failed Colonoscopy), Billing and Coding A56632 (Billing and Coding: Colonoscopy/Sigmoidoscopy/Proctosigmoidoscopy) carry the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A55069: Billing and Coding: Screening Colonoscopy Converted to a Diagnostic and/or Therapeutic Colonoscopy (Billing and Coding, effective 2025-10-01)

Covered ICD-10-CM codes
3
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
7
Full article
cms.gov record
First 3 covered ICD-10-CM codes in A55069
ICD-10-CMDescription (FY2027)
Z12.11Encounter for screening for malignant neoplasm of colon
Z15.060Genetic susceptibility to colorectal cancer
Z80.0Family history of malignant neoplasm of digestive organs

Procedure codes: 45380, 45381, 45382, 45384, 45385, G0105 (Colorectal cancer screening; colonoscopy on individual at high risk), G2204 (Patients between 45 and 85 years of age who received a screening colonoscopy during the performance period).

A55227: Billing and Coding: Incomplete Colonoscopy/Failed Colonoscopy (Billing and Coding, effective 2025-10-01)

Covered ICD-10-CM codes
3
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
4
Full article
cms.gov record
First 3 covered ICD-10-CM codes in A55227
ICD-10-CMDescription (FY2027)
Z12.11Encounter for screening for malignant neoplasm of colon
Z15.060Genetic susceptibility to colorectal cancer
Z80.0Family history of malignant neoplasm of digestive organs

Procedure codes: 44388, 45378, G0105 (Colorectal cancer screening; colonoscopy on individual at high risk), G0121 (Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk).

A56632: Billing and Coding: Colonoscopy/Sigmoidoscopy/Proctosigmoidoscopy (Billing and Coding, effective 2025-10-01)

Covered ICD-10-CM codes
558
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
51
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56632
ICD-10-CMDescription (FY2027)
A03.9Shigellosis, unspecified
A04.3Enterohemorrhagic Escherichia coli infection
A04.5Campylobacter enteritis
A04.6Enteritis due to Yersinia enterocolitica
A04.71Enterocolitis due to Clostridium difficile, recurrent
A04.72Enterocolitis due to Clostridium difficile, not specified as recurrent
A04.8Other specified bacterial intestinal infections
A04.9Bacterial intestinal infection, unspecified
A06.1Chronic intestinal amebiasis
A06.2Amebic nondysenteric colitis
A06.9Amebiasis, unspecified
A07.0Balantidiasis
A07.3Isosporiasis
A07.8Other specified protozoal intestinal diseases
A08.0Rotaviral enteritis
A08.11Acute gastroenteropathy due to Norwalk agent
A08.19Acute gastroenteropathy due to other small round viruses
A08.2Adenoviral enteritis
A08.31Calicivirus enteritis
A08.32Astrovirus enteritis
A08.39Other viral enteritis
A09Infectious gastroenteritis and colitis, unspecified
A18.31Tuberculous peritonitis
A18.32Tuberculous enteritis

Procedure codes: 44388, 44389, 44390, 44391, 44392, 44394, 44401, 44402, 45300, 45303, 45305, 45307, 45308, 45309, 45315, 45317, 45320, 45321, 45327, 45330, 45331, 45332, 45333, 45334, 45335, 45337, 45338, 45340, 45341, 45342, 45346, 45347, 45349, 45378, 45379, 45380, 45381, 45382, 45384, 45385 and 11 more in the article.

Coverage indications, limitations and medical necessity

This Local Coverage Determination (LCD) addresses the colonoscopies that are NOT performed for colorectal cancer screening. Colorectal cancer screening is a separate benefit with specific guidelines.

Proctosigmoidoscopy is the examination of the rectum and sigmoid colon.

Sigmoidoscopy is the examination of the entire rectum, sigmoid colon and may include examination of a portion of the descending colon.

Colonoscopy is the examination of the entire colon, from the rectum to the cecum, and may include the examination of the terminal ileum or small intestine proximal to an anastomosis. The colonoscope is inserted anally (or through a stoma) and is advanced optimally through the large intestine under direct vision, using the scope's optical system. See the Centers for Medicare and Medicaid Services (CMS) Internet-Only Manual, Pub. 100-04, Medicare Claims Processing Manual, Chapter 12, §30.1B Digestive System - Incomplete Colonoscopies for the definition of incomplete colonoscopies.

Covered Indications:

1. For evaluation of an abnormality discovered on barium enema and/or other imaging technique that is likely to be clinically significant, such as a filling defect or stricture or an inadequate examination;

2. For evaluation of unexplained gastrointestinal (GI) bleeding;

• Hematochezia not thought to be from rectum or perianal source

• Melena of unknown origin

• Presence of fecal occult blood

3. For unexplained iron deficiency anemia;

4. For surveillance of colonic neoplasia;

• For examination to evaluate the entire colon for synchronous cancer or polyps in a patient with treatable cancer or polyps.

• For follow-up 1 year after surgery for treatment of colorectal cancer when the patient is identified as being at high-risk for colon cancer and is eligible for continued screenings at 24-month intervals.

• For follow-up at least 3-6 months after colonoscopic removal of a large sessile adenoma (i.e., greater than 2 cm in greatest dimension).

• For patients with Crohn’s colitis, chronic ulcerative colitis (UC), pancolitis of greater than 7 years duration or left-sided colitis of over 15 years duration (no surveillance needed for disease limited to rectosigmoid) may have a colonoscopy every 1-2 years for multiple biopsies to detect cancer and/or dysplasia.

5. For chronic inflammatory bowel disease (IBD) of the colon (if a more precise diagnosis or if a determination of the extent of activity of disease will influence immediate management);

6. For clinically significant diarrhea of unexplained origin with additional findings (e.g., weight loss or negative stool cultures persisting for more than 3 weeks);

7. For intraoperative identification of the site of a lesion that cannot be detected by palpation or gross inspection at surgery (e.g., polypectomy site or location of a bleeding source);

8. For evaluation of acute colonic ischemia/ischemic bowel disease;

9. For evaluation of a patient with Streptococcus bovis (S. bovis) endocarditis or bacteremia;

10. For treatment of bleeding from such lesions as vascular anomalies, ulceration and neoplasia;

11. For removal of a foreign body;

12. For excision of colonic polyps;

13. For decompression of pseudo-obstruction of the colon (Olgilvie’s Syndrome) following a trial of neostigmine or cathartics or a documented reason that this would be either unsafe or inappropriate for the beneficiary;

14. For treatment of colonic volvulus or stricture;

15. For evaluation of an unexplained, new-onset constipation, refractory to medical therapy;

16. For evaluation of an anorectal polyp (adenomatous polyp only); or,

17. For palliative treatment of stenosing, bleeding neoplasms (e.g., laser, electrocoagulation, stenting).

Limitations:

Endoscopy is generally not covered for treating the indications below. Additional documentation should be submitted indicating the medical necessity of the procedure for review.

• Chronic, stable, irritable bowel syndrome (IBS), or chronic abdominal pain. There are unusual exceptions in which colonoscopy may be done to rule out organic disease, especially if symptoms are unresponsive to therapy;

• Acute diarrhea;

• Hemorrhoids;

• Metastatic adenocarcinoma of unknown primary site in the absence of colonic symptoms, when it will not influence management;

• Routine follow-up of IBD (except for cancer surveillance in Crohn’s disease and chronic UC);

• Routine examination of the colon in patients about to undergo elective abdominal surgery for non-colonic disease;

• Upper GI bleeding or melena with a demonstrated upper GI source; or,

• Bright red rectal bleeding with a convincing anorectal source on sigmoidoscopy and no other symptoms suggestive of a more proximal bleeding source.

Colonoscopy/Sigmoidoscopy/Proctosigmoidoscopy are generally not covered for:

• Fulminant colitis;

• Possible perforated viscus;

• Acute severe diverticulitis; or,

• Diverticulosis is not usually considered an indication for a diagnostic or therapeutic colonoscopy/sigmoidoscopy/proctosigmoidoscopy but may be reported on the claim when this condition is found to be the final diagnosis.

Other Comments:

Limitation of liability and refund requirements apply when denials are likely, based on either medical necessity or other coverage reasons. The provider/supplier must notify the beneficiary in writing prior to rendering the service if the provider/supplier is aware that the test, item or procedure may not be covered by Medicare. The limitation of liability and refund requirements do not apply when the test, item or procedure is statutorily excluded, has no Medicare benefit category, or is rendered for screening purposes.

Summary of evidence (opening)

Background

Rigid endoscopes have been used in medicine since the early 19th century. 1 Around the middle of the 20th century, the diagnosis and treatment of colon diseases started to make significant advancements. The development and improvement of endoscopic tools of the lower GI tract, particularly flexible fiber optic endoscopes of varying lengths (depending on most proximal area of the colon to be visualized), served as an alternative to barium enemas for visualization of colonic abnormalities. The flexible fiber optic endoscopes allowed biopsies and the removal of polyps at proximal colonic locations beyond the reach of rigid endoscopes that could previously only be achieved by surgery. 2-4 Rigid proctosigmoidoscopy has largely been replaced by flexible endoscopy; however, rigid endoscopy may be used to evaluate the distal large bowel and rectum. This allows relatively easy washout of blood in the distal colon for visualization. 5 Rigid proctosigmoidoscopy is believed by some to provide more accurate localization of malignancies than fiber optic endoscopy techniques. 6-7

One of the early studies of colonoscopy suggested not only a therapeutic but potential diagnostic advantage over imaging techniques. The study compared findings on barium contrast enema radiography and colonoscopy for the first 700 patients to undergo a colonoscopy at a single institution. 8 Colonic neoplasia was the most common indication for colonoscopy, being present in 344 of the 700 patients. IBD was the indication in 133 patients. Other indications in decreasing order of frequency included x-ray negative colonic bleeding, IBS, x-ray negative diarrhea and obstruction. In a comparison of Malmo double contrast barium enema findings vs colonoscopy findings, they noted that the barium enema found 97% of polyps > 1 cm detected by colonoscopy, but only 78% of small polyps. Conventional barium enema evaluation was less successful. In cases of UC, they found that barium enema findings agreed with colonoscopy with biopsy findings in 68% of the cases. However, 18% of cases were found to have a substantial underestimate of the extent of disease with the barium enema and the barium enema was normal for 14% of cases while colonoscopy and biopsy revealed total colitis.

Evaluation of Abnormal Findings on Radiography

The contractor cites 59 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2015-10-01
Current revision effective
2024-12-19
Last reviewed by the contractor
2024-11-11
MCD version
67
Derived from
L31549

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L34454 cover?

This Local Coverage Determination (LCD) addresses the colonoscopies that are NOT performed for colorectal cancer screening. Colorectal cancer screening is a separate benefit with specific guidelines. The full 834-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L34454 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L34454?

The companion billing and coding article A55069 lists 3 ICD-10-CM codes in 1 group that support medical necessity; the first 3 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L34454?

A denial under LCD L34454 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A55069's 3 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.